Business
Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer.
Companies strengthen their leadership teams and executive boards with this week’s Movers & Shakers.
Pinpoint Therapeutics believes that its approach to treat therapy-resistant cancers also may be effective against COVID-19.
With all the similarities, it should be emphasized that there are several significant differences between the two pandemics.
Under terms of the deal, Aurobindo would pay $900 million upfront with an additional $100 million in milestone payments. However, in a filing with the Securities and Exchange Commission, the company announced it had terminated that agreement.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
On Wednesday, the judge overseeing Holmes’ case set for late July refused to change the trial date after her defense team made the request.
On March 25, the American Medical Association, American Pharmacist Association and Americans Society of Health-System Pharmacists issued a statement in response to media reports that physicians and pharmacists were hoarding supplies of the drugs for their own use.
“Companies active in the fight against COVID-19 will have plenty of funding, and those targeting severe unmet needs will weather the storm better than others. But, for the rest, it will be rough for the next 12 months,” said Otello Stampacchia, founder of Omega Funds.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.